Long-Term Effectiveness of Tofacitinib in Rheumatoid Arthritis
Author Information
Author(s): Marta Priora, Andracco R., Eleonora Celletti, Myriam Di Penta, Alberto Lo Gullo, Marino Paroli, Elena Bravi, Romina Andracco, Valeria Nucera, Francesca Ometto, Federica Lumetti, Antonella Farina, Patrizia Del Medico, Matteo Colina, Viviana Ravagnani, Palma Scolieri, Maddalena Larosa, Elisa Visalli, Olga Addimanda, Rosetta Vitetta, Alessandro Volpe, Alessandra Bezzi, Francesco Girelli, Aldo Biagio Molica Colella, Rosalba Caccavale, Eleonora Di Donato, Giuditta Adorni, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Emanuela Sabatini, Ilaria Platè, Natalia Mansueto, Aurora Ianniello, Enrico Fusaro, Maria Chiara Ditto, Vincenzo Bruzzese, Dario Camellino, Gerolamo Bianchi, Francesca Serale, Rosario Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Roberta Foti, Massimo Reta, Alessia Fiorenza, Guido Rovera, Antonio Marchetta, Maria Cristina Focherini, Fabio Mascella, Simone Bernardi, Gilda Sandri, Dilia Giuggioli, Carlo Salvarani, Veronica Franchina, Francesco Molica, Giulio Ferrero, Alarico Ariani, Simone Parisi
Primary Institution: Rheumatology Day Hospital and Outpatient Clinic, ASL CN1, Cuneo, Italy
Hypothesis
What are the long-term effectiveness and predictors of response to Tofacitinib in rheumatoid arthritis patients with different cardiovascular risk profiles?
Conclusion
Tofacitinib is effective in reducing disease activity in rheumatoid arthritis patients, regardless of their cardiovascular risk status.
Supporting Evidence
- Tofacitinib showed similar effectiveness in both high- and low-risk cardiovascular subgroups.
- Significant reductions in disease activity were observed at both 6 and 12 months.
- Age negatively impacted treatment response, indicating the role of immunosenescence.
Takeaway
Tofacitinib helps people with rheumatoid arthritis feel better, even if they have heart risks.
Methodology
This was a retrospective, multicenter observational study involving 213 RA patients treated with Tofacitinib, with data collected on demographics, clinical history, and disease activity.
Potential Biases
Data collection from multiple centers could lead to heterogeneity in patient management.
Limitations
The retrospective design may introduce selection bias, and the limited number of patients may reduce statistical power.
Participant Demographics
The study included 213 patients, with 39 males and 174 females, median age of 60 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website